On November 29, Glonghui reported that hainan huluwa pharmaceutical group (605199.SH) announced that its stocks have experienced a continuous daily price limit rise from November 26, 2024, to November 29, 2024, with a cumulative increase of 46.40%. The turnover ratio over the last four trading days has reached 19.83%. The company specifically reminds investors to be aware of risks in the secondary market, make rational decisions, and invest cautiously. After the company's self-inspection and written verification with its controlling shareholder and actual controller, it is confirmed that as of the date of this announcement, there are no significant matters that should be disclosed but have not been disclosed.